Insight

Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies

Photo from Aaron Goodman/X

Mar 3, 2024, 17:02

Aaron Goodman: Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies

Aaron Goodman shared an X post by Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, adding:

“Patients with Erdheim Chester disease should be started on much lower doses of targeted therapies (BRAFi, MEKi). This disease is like CML with exquisite and deep responses to single-agent targeted therapy. Just start low (I usually start 25 to 50% dose reduction).”

Quoting Razelle Kurzrock’s post:

“Patients with Erdheim Chester Disease need lowered doses — but they respond.”

Source: Aaron Goodman/X and Razelle Kurzrock/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman BRAF inhibitor cancer CML Erdheim Chester disease Ila Saunders Medical College of Wisconsin Cancer Center MEK inhibitor OncoDaily Oncology Razelle Kurzrock targeted therapy The University of California San Diego

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage